Literature DB >> 27613697

Context-Specific Function of S6K2 in Th Cell Differentiation.

Christine Pai1, Craig M Walsh1, David A Fruman2.   

Abstract

The mammalian target of rapamycin (mTOR) is essential for Th cell proliferation and effector differentiation, making the mTOR signaling network an attractive immunomodulatory target for autoimmune-related diseases. Although direct targeting of mTOR complex-1 (mTORC1) with rapamycin can provide clinical benefit, targeting downstream enzymes has the potential to offer more selective immunosuppression. In this study, we evaluated p70 ribosomal protein S6 Kinase 2 (S6K2), a downstream effector of mTORC1, for its role in T cell function and autoimmunity. S6K2 is a direct substrate of mTORC1, with a potential role in Th17 differentiation suggested by biochemical studies. Using a genetic approach with S6K2 knockout mice, we found that S6K2 loss reduces Th17 skewing and increases regulatory T cell differentiation in vitro when cultured in RPMI 1640 media. However, S6K2 was dispensable for Th17 differentiation in IMDM. In an in vivo experimental autoimmune encephalomyelitis model in which rapamycin suppresses disease, S6K2 knockout mice did not exhibit differences in clinical score or Th17 differentiation. These results suggest that S6K2 is dispensable for Th17-driven autoimmunity and highlight how distinct experimental conditions can produce significantly different results in T cell differentiation.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27613697      PMCID: PMC5101169          DOI: 10.4049/jimmunol.1600167

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

1.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Authors:  Andrew Y Choo; Sang-Oh Yoon; Sang Gyun Kim; Philippe P Roux; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

2.  Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling.

Authors:  Yonghao Yu; Sang-Oh Yoon; George Poulogiannis; Qian Yang; Xiaoju Max Ma; Judit Villén; Neil Kubica; Gregory R Hoffman; Lewis C Cantley; Steven P Gygi; John Blenis
Journal:  Science       Date:  2011-06-10       Impact factor: 47.728

3.  Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation.

Authors:  Marianna Esposito; Francesca Ruffini; Matteo Bellone; Nicola Gagliani; Manuela Battaglia; Gianvito Martino; Roberto Furlan
Journal:  J Neuroimmunol       Date:  2010-02-11       Impact factor: 3.478

4.  Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases.

Authors:  R P Carlson; W L Baeder; R G Caccese; L M Warner; S N Sehgal
Journal:  Ann N Y Acad Sci       Date:  1993-06-23       Impact factor: 5.691

Review 5.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

Review 6.  Adverse events associated with mTOR inhibitors.

Authors:  Nicolas Pallet; Christophe Legendre
Journal:  Expert Opin Drug Saf       Date:  2012-12-20       Impact factor: 4.250

7.  Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis.

Authors:  Aaron M Robitaille; Stefan Christen; Mitsugu Shimobayashi; Marion Cornu; Luca L Fava; Suzette Moes; Cristina Prescianotto-Baschong; Uwe Sauer; Paul Jenoe; Michael N Hall
Journal:  Science       Date:  2013-02-21       Impact factor: 47.728

Review 8.  Signaling by the phosphoinositide 3-kinase family in immune cells.

Authors:  Klaus Okkenhaug
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

9.  Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.

Authors:  Zhi-Wei Lai; Rebecca Borsuk; Ashwini Shadakshari; Jianghong Yu; Maha Dawood; Ricardo Garcia; Lisa Francis; Hajra Tily; Adam Bartos; Stephen V Faraone; Paul Phillips; Andras Perl
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

10.  Mechanistic Target of Rapamycin Complex 1/S6 Kinase 1 Signals Influence T Cell Activation Independently of Ribosomal Protein S6 Phosphorylation.

Authors:  Robert J Salmond; Rebecca J Brownlie; Oded Meyuhas; Rose Zamoyska
Journal:  J Immunol       Date:  2015-10-09       Impact factor: 5.422

View more
  7 in total

1.  Locus Mapping, Molecular Cloning, and Expression Analysis of rps6kb2, a Novel Metamorphosis-Related Gene in Chinese Tongue Sole (Cynoglossus semilaevis).

Authors:  Yang Liu; Min Wei; Hua Guo; Changwei Shao; Liang Meng; Wenteng Xu; Na Wang; Lei Wang; Deborah M Power; Jilun Hou; Shahid Mahboob; Zhongkai Cui; Yingming Yang; Yangzhen Li; Fazhen Zhao; Songlin Chen
Journal:  Mar Biotechnol (NY)       Date:  2017-08-05       Impact factor: 3.619

Review 2.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

3.  Predicting mechanism of action of cellular perturbations with pathway activity signatures.

Authors:  Yan Ren; Siva Sivaganesan; Nicholas A Clark; Lixia Zhang; Jacek Biesiada; Wen Niu; David R Plas; Mario Medvedovic
Journal:  Bioinformatics       Date:  2020-09-15       Impact factor: 6.937

4.  Regulation of anti-apoptotic Bcl-2 family protein Mcl-1 by S6 kinase 2.

Authors:  Alakananda Basu; Savitha Sridharan
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

Review 5.  Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?

Authors:  Ebru Aydin; Sebastian Faehling; Mariam Saleh; Laura Llaó Cid; Martina Seiffert; Philipp M Roessner
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

Review 6.  "Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology.

Authors:  Sophie Jung; Laura Gámez-Díaz; Michele Proietti; Bodo Grimbacher
Journal:  Front Immunol       Date:  2018-05-09       Impact factor: 7.561

7.  Comparison of rapamycin and methylprednisolone for treating inflammatory muscle disease in a murine model of experimental autoimmune myositis.

Authors:  Juan Kang; Dongyun Feng; Feng Yang; Xiaojia Tian; Wenjuan Han; Hongge Jia
Journal:  Exp Ther Med       Date:  2020-05-05       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.